Semaglutide and Gallbladder Disease: What GLP-1 Patients Need to Know

# Semaglutide and Gallbladder Disease: What GLP-1 Patients Need to Know

Gallbladder disease is one of the less-discussed but clinically significant risks associated with GLP-1 medications. It appears in the prescribing information for semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro), and understanding it helps patients recognize symptoms early.

The Basics

GLP-1 receptor agonists are associated with an increased incidence of: - Cholelithiasis (gallstones) - Cholecystitis (gallbladder inflammation) - Cholestasis (bile flow impairment)

In the STEP trials (semaglutide for weight management), gallbladder disorders occurred in approximately 2.6% of patients on semaglutide 2.4mg vs. 1.2% on placebo — roughly double the baseline rate.

Absolute risk is still relatively low, but the increase is real and worth understanding.

Why Does It Happen?

Two mechanisms are at play:

### 1. Rapid Weight Loss

The most established risk factor for gallstones is rapid weight loss — regardless of method. When you lose weight quickly, the liver secretes more cholesterol into bile (mobilizing fat stores), while the reduced caloric intake means less fat in your diet stimulates bile flow.

The combination produces bile that is supersaturated with cholesterol — the primary substrate of most gallstones.

Any intervention causing rapid weight loss (bariatric surgery, VLCD diets, GLP-1 medications) carries elevated gallstone risk for this reason. Bariatric surgery — the fastest weight loss method — has a gallstone rate of up to 30-40% without prophylactic intervention.

### 2. GLP-1 Receptor Activation Slows Gallbladder Motility

GLP-1 receptors are present in the gallbladder. When activated, they reduce gallbladder contractions. The gallbladder contracts in response to fat in the diet, releasing bile to aid fat digestion.

Reduced contractions mean bile sits in the gallbladder longer. Static bile is more likely to crystallize into stones.

This is a direct pharmacological effect independent of weight loss — meaning even patients on lower doses or losing weight slowly may have some risk.

How Common Is Gallstone Formation on GLP-1?

Estimates vary by trial and population, but: - Semaglutide (Wegovy dose): ~2-3% incidence of gallbladder events in STEP trials - Tirzepatide: Similar rates reported in SURMOUNT trials - Bariatric surgery for comparison: 30-40% without prophylaxis, ~6% with ursodiol prophylaxis

Most gallstones are asymptomatic and discovered incidentally. Clinically significant events (cholecystitis, choledocholithiasis requiring intervention) are less common — but still elevated compared to placebo.

Who's at Higher Risk?

Baseline risk factors for gallstones amplify the GLP-1-associated risk:

• Female sex (2x baseline risk vs. men)
• Obesity (independent risk factor)
• Age 40+
• Rapid weight loss pace (>1.5 lbs/week sustained)
• History of gallstones or family history
• Pregnancy or oral estrogen use
• Very low-fat diet
• Sedentary lifestyle

Patients with multiple risk factors may benefit from baseline gallbladder ultrasound before starting GLP-1 treatment and periodic monitoring.

Symptoms to Watch For

Most gallstones are silent. When symptoms do occur:

Biliary colic (most common symptomatic presentation): - Sudden, severe pain in the right upper abdomen or center of the abdomen - Pain may radiate to the right shoulder or back - Typically occurs 30-60 minutes after eating (particularly fatty meals) - Episodes last minutes to hours, then resolve

Cholecystitis (gallbladder inflammation — more serious): - Right upper quadrant pain that persists >6 hours - Fever - Nausea/vomiting - Tenderness on palpation of the right side

Choledocholithiasis (stone in bile duct — urgent): - Severe upper abdominal pain - Jaundice (yellowing of skin/eyes) - Dark urine, light-colored stools - Fever and chills (suggests infection — requires emergency care)

If you experience persistent severe right upper abdominal pain, fever, or jaundice while on a GLP-1 medication: seek medical evaluation promptly.

Prevention Strategies

Slower weight loss: The most impactful strategy. Limiting loss to 0.5-1 lb/week significantly reduces bile saturation. On GLP-1, this can sometimes be managed through slower dose titration, though the medication's effects on appetite aren't fully controllable.

Don't go too low-fat: Some fat intake is necessary to stimulate gallbladder contractions and prevent bile stasis. Very low-fat diets (< 10g fat/day) are associated with higher gallstone risk. Include moderate amounts of healthy fats: olive oil, nuts, avocado, fatty fish.

Ursodeoxycholic acid (ursodiol): A bile acid supplement that reduces cholesterol supersaturation. Used prophylactically in bariatric surgery patients (500-600mg/day cuts gallstone risk by ~60%). Some physicians prescribe it for high-risk GLP-1 patients. Not standard of care, but evidence-supported.

Regular meals with fat: Eating regular meals with some fat keeps the gallbladder contracting regularly, reducing stasis.

Should I Stop GLP-1 If I Develop Gallstones?

Not necessarily — and that's a conversation for your physician. Many patients develop asymptomatic gallstones that never cause problems. The risk-benefit calculation (significant cardiovascular, metabolic, and weight management benefits of GLP-1) versus gallstone risk (mostly asymptomatic, manageable when symptomatic) often favors continuing treatment.

Active cholecystitis typically requires temporary discontinuation until resolved. Your physician will guide this decision.

At Marrow, our physicians review your complete medical history — including gallbladder risk factors — before and during GLP-1 prescribing. [Start your consultation →](/start)